CYP2C19 Inducers

    CYP2C19 inducers include, but are not limited to, carbamazepine, efavirenz, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John’s wort. See glossary page for more information.


    CYP2C19 inducers are compounds that increase the activity of the CYP2C19 enzyme, which can increase drug metabolism, potentially impacting the effects of drug therapy.

    CYP2C19 is a cytochrome P450 (CYP) enzyme found primarily in the liver that is involved in the metabolism of any medications that are CYP2C19 substrates.[1] CYP2C19 inducers can increase the body’s metabolism of these medications.

    The table below outlines some of the most common or clinically relevant CYP2C19 inducers.[2][1][3] Importantly, this list is not exhaustive.

    CYP2C19 Inducers
    St. John’s wort


    1. ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
    2. ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
    3. ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)